Vera Therapeutics (VERA) Enterprise Value (2021 - 2026)

Vera Therapeutics (VERA) has 7 years of Enterprise Value data on file, last reported at -$596.8 million in Q1 2026.

• Quarterly Enterprise Value fell 1.17% year-over-year to -$596.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$596.8 million (down 1.17% YoY) and the FY2025 annual result came in at -$714.6 million, down 11.51% from the prior year.
• Enterprise Value rose to -$596.8 million in Q1 2026, from -$714.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$114.4 million in Q3 2022 to a low of -$714.6 million in Q4 2025.
• A 5-year average of -$349.9 million and a median of -$353.3 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value tumbled 298.75% — and 2026, when it slipped 1.17%.
• Tracing VERA's Enterprise Value over 5 years: stood at -$114.7 million in 2022, then sank by 40.18% to -$160.7 million in 2023, then plunged by 298.75% to -$640.9 million in 2024, then decreased by 11.51% to -$714.6 million in 2025, then rose by 16.49% to -$596.8 million in 2026.
• The last three Enterprise Value figures came in at -$596.8 million (Q1 2026), -$714.6 million (Q4 2025), and -$497.4 million (Q3 2025), per Business Quant data.